Continuing Medical Education (CME)
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Monday, October 15, 2018. A link to the CME evaluation will be emailed to attendees after the meeting.
This conference will serve as an update on current progress made in hepatic fibrosis including new discoveries shaping the field of basic research of fibrosis and the role of the microbiome and gut-liver axis. In addition, new information about NAFLD and the potential role of nonparenchymal cells in fibrosis, with an emphasis on nonparenchymal-stellate cell crosstalk will be discussed. Also, the translational aspects of fibrosis and cirrhosis, including translation of findings into humans and discoveries that may lead to novel therapies will be discussed.
Upon completion of this activity, learners will be able to:
This activity was planned in the context of the following ACGME/IOM/IPEC competencies: Patient-centered Care, Work in Interdisciplinary Teams, Evidence-based Practice, Quality Improvement Utilize Informatics, Medical Knowledge, Teams and Teamwork and Translating Data From the Bench to Medical Therapy.